Marwa G El-Gazzar1, Nessma H Nafie1, Alessio Nocentini2, Mostafa M Ghorab1, Helmi I Heiba1, Claudiu T Supuran2. 1. a Department of Drug Radiation Research, National Center for Radiation Research and Technology (NCRRT) , Egyptian Atomic Energy Authority (EAEA) , Cairo , Egypt. 2. b NEUROFARBA Department, Pharmaceutical and Nutraceutical Sciences Section , University of Florence , Firenze , Italy.
Abstract
We report the synthesis and characterisation of a novel series of triazole benzenesulfonamide derivatives, which incorporate the general pharmacophore associated with carbonic anhydrase (CA, EC 4.2.1.1) inhibitors. The synthesised compounds were tested in vitro against four human carbonic anhydrase (hCA, EC 4.2.1.1) isozymes, hCA I, hCA II, hCA IV and hCA IX. The obtained results showed that the tumour-associated hCA IX was the most sensitive to inhibition with the synthesised derivatives, with the triazolo-pyridine benzenesulfonamides 14, 16 and 17 being the most effective inhibitors. Some selected compounds were chosen for a single dose anti-proliferative activity testing against a panel of 57 human tumour cell lines and show some anti-proliferative activity ex vivo.
We report the synthesis and characterisation of a novel series of n class="Chemical">triazole benzenesulfonamide derivatives, which incorporate the general pharmacophore associated with carbonic anhydrase (CA, EC 4.2.1.1) inhibitors. The synthesised compounds were tested in vitro against four humancarbonic anhydrase (hCA, EC 4.2.1.1) isozymes, hCA I, hCA II, hCA IV and hCA IX. The obtained results showed that the tumour-associated hCA IX was the most sensitive to inhibition with the synthesised derivatives, with the triazolo-pyridine benzenesulfonamides 14, 16 and 17 being the most effective inhibitors. Some selected compounds were chosen for a single dose anti-proliferative activity testing against a panel of 57 humantumour cell lines and show some anti-proliferative activity ex vivo.
Entities:
Keywords:
1,2,3-triazole; Carbonic anhydrase; anti-proliferative; benzenesulfonamide; hCA IX
Authors: Mostafa M Ghorab; Mariangela Ceruso; Mansour S Alsaid; Yassin M Nissan; Reem K Arafa; Claudiu T Supuran Journal: Eur J Med Chem Date: 2014-09-19 Impact factor: 6.514
Authors: Alessio Nocentini; Silvia Bua; Carrie L Lomelino; Robert McKenna; Marta Menicatti; Gianluca Bartolucci; Barbara Tenci; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Paola Gratteri; Claudiu T Supuran Journal: ACS Med Chem Lett Date: 2017-11-21 Impact factor: 4.345
Authors: Pawel Swietach; Shalini Patiar; Claudiu T Supuran; Adrian L Harris; Richard D Vaughan-Jones Journal: J Biol Chem Date: 2009-05-19 Impact factor: 5.157
Authors: Yi-Hsuan Tsai; Carla M Borini Etichetti; Carolina Di Benedetto; Javier E Girardini; Felipe Terra Martins; Rolando A Spanevello; Alejandra G Suárez; Ariel M Sarotti Journal: J Org Chem Date: 2018-03-08 Impact factor: 4.354
Authors: Claudiu T Supuran; Vincenzo Alterio; Anna Di Fiore; Katia D' Ambrosio; Fabrizio Carta; Simona Maria Monti; Giuseppina De Simone Journal: Med Res Rev Date: 2018-04-10 Impact factor: 12.944
Authors: Ioanna Ledaki; Alan McIntyre; Simon Wigfield; Francesca Buffa; Simon McGowan; Dilair Baban; Ji-Liang Li; Adrian L Harris Journal: Oncotarget Date: 2015-08-14
Authors: Siham A Alissa; Hanan A Alghulikah; Zeid A ALOthman; Sameh M Osman; Sonia Del Prete; Clemente Capasso; Alessio Nocentini; Claudiu T Supuran Journal: J Enzyme Inhib Med Chem Date: 2020-12 Impact factor: 5.051
Authors: Siham A Alissa; Hanan A Alghulikah; Zeid A Alothman; Sameh M Osman; Sonia Del Prete; Clemente Capasso; Alessio Nocentini; Claudiu T Supuran Journal: J Enzyme Inhib Med Chem Date: 2020-12 Impact factor: 5.051